Sanofi, Regeneron’s Libtayo cleared for basal cell carcinoma
Libtayo is the first immunotherapy indicated for patients with advanced basal cell carcinoma
Read More
Tag: BCC
Sanofi/Regeneron’s Libtayo shows benefit in BCC
BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
